About the Disease
Mucopolysaccharidosis (MPS) is an inherited metabolic disease in which the body either does not produce enough enzymes required to break down sugars into simpler molecules, or the body produces enzymes that do not work properly. Over time, molecules called glycosaminoglycans (sugar carbohydrates in each of our cells that help build bone, cartilage, tendons, corneas, skin, and connective tissue) collect in the cells, blood, and connective tissues, resulting in permanent, progressive cellular damage. The cellular damage affects the appearance, physical abilities, organ and system functioning, as well as cognitive development.
Several different clinical types of mucopolysaccharidosis have been identified.
MPS I, Hurler, Hurler-Scheie, and Scheie
MPS I is a condition that affects many different organs and tissues. Individuals with severe cases experience a rapid disease progression and a decline in intellectual function. Developmental delay is typically present by age 1, and those severely affected lose basic functional skills and shortened lifespan, sometimes only living into late childhood.
MPS II, Hunter syndrome
MPS II is a condition that occurs almost exclusively in males. It affects many different organs and tissues. Individuals with a severe form experience a rapid disease progression and a decline in intellectual function, and begin to lose basic functional skills between the ages of 6 and 8 with a life expectancy of 10 to 20 years.
MPS III, Sanfilippo syndrome
MPS III is a condition that affects the brain and spinal cord, often causing delayed speech, behavior and sleep problems in children. Individuals experience progressive intellectual disability and the loss of previously acquired skills, and in later stages may develop seizures and movement disorders.
MPS IV, Morquio syndrome
MPS IV is a condition that affects the skeleton, including short stature, knock knees, and abnormalities of the ribs, chest, spine, hips, and wrists. In addition, the cornea typically becomes cloudy, which may cause vision loss or recurrent ear infections may cause hearing loss. The life expectancy of those with severe cases is only until late childhood or adolescence.
MPS VI, Maroteaux-Lamy syndrome
MPS VI is a condition that causes many tissues and organs to enlarge and become inflamed or scarred. Skeletal abnormalities are also common. Without treatment, the life expectancy of those with severe symptoms is only until late childhood or adolescence.
MPS VII, Sly syndrome
MPS VII is a condition that affects most tissues and organs, and can cause various skeletal abnormalities. Severe cases are characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth. Most babies are stillborn or die soon after birth, while those who survive may live into adolescence or adulthood. Heart disease and airway obstruction is the major cause of death.
About our Patient Care
Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide
counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of treatment, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.
In-Home Patient- and Family-Centric Care
We administer a nationwide nursing network, allowing patients to pursue in-home treatment or receive training on self-administrated drugs. Our nurses are ideally positioned to establish a partnership with patients and their families in order to provide clinical education and coaching that strengthen the patient's capacity to achieve therapy goals.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.
We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Aldurazyme (laronidase) MPS I
Brand Name | Aldurazyme
Manufacturer | Genzyme
Route of Administration | Intravenous (IV) infusion
Approved Indication | Patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms
Self-Administration | No
Product Website | www.aldurazyme.com